3B circumscribed masses: to assess or not to assess?
2008

Assessing 3B Circumscribed Masses in Breast Cancer Screening

Sample size: 388 Commentary Evidence: moderate

Author Information

Author(s): Bonetti F, Manfrin E

Primary Institution: Department of Pathology, Verona University, Verona, Italy

Hypothesis

Is it beneficial to assess benign-looking 3B lesions in breast cancer screening?

Conclusion

Assessing 3B lesions may increase cancer detection but does not guarantee a reduction in mortality.

Supporting Evidence

  • 8.3% of 3B lesions were found to be malignant in a previous study.
  • The global FNAC accuracy in Verona was 99.3% for defining breast lesions.
  • 19 out of 388 circumscribed 3B lesions were identified as carcinomas.

Takeaway

Doctors are trying to figure out if checking certain breast lumps is helpful, but it might not actually save lives.

Methodology

The study involved cyto-histological characterization of 388 circumscribed 3B lesions.

Potential Biases

Pressure from patients for high diagnostic quality may influence decision-making.

Limitations

There is no definitive proof that detecting more tumors will reduce mortality.

Participant Demographics

Participants were women attending the Verona Breast Cancer Screening Program.

Digital Object Identifier (DOI)

10.1038/sj.bjc.6604500

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication